spacer
home > ebr > summer 2007 > risky business in the globalised economy
PUBLICATIONS
European Biopharmaceutical Review

Risky Business in the Globalised Economy

Tom Roche at FM Global examines an approach designed to provide vital company protection for the long term as new risks emerge

All companies take risks – it’s a natural part of succeeding in a competitive business environment. In the pharmaceutical business, as in many others, it’s part of the art of commercial success to calculate a risk – the likelihood, the need to take it, the consequences if the risk becomes the reality – and to plan your business moves accordingly, almost certainly incorporating a healthy dose of risk prevention. That’s the theory, at least, and operating in a globalised economy that has increased the potential for risk at just about every step, it should also be the practice.

For all the organisational sophistication and slick operational performance at the heart of global success, the need for any commercial enterprise – including a major pharmaceutical company – to identify and consider at each stage the possibility of what could go wrong has not diminished. If anything, it has increased, because whether it’s a ‘big bang’ or something far more insidious and systemic, for every benefit globalisation offers there are potential pitfalls which a company ignores at its peril.

REPUTATIONS ON THE LINE

There have been several high profile examples of the reputational risks pharmaceutical companies run in the day-today task of bringing new products to market. Newspapers screaming ‘drug test disaster’ do circulation figures no harm at all, and those unfortunate stories are not easily forgotten. But commercial risks – events and occurrences that can severely damage a corporation if not properly managed – need not be of the headline-making variety.

Recent research in the US and Europe with executives from the world’s leading companies demonstrated that, in a global business, disruption to the supply chain comes second only to competition as a threat to a company’s well-being. In other words, the principle risk to the existence of a global business is largely defined by the way the company itself sets up its own business. An adequate response to this finding is a commercial imperative.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
After graduating from Lancaster University with Bachelor’s and Master’s degrees in Mechanical and Electronic Engineering, Tom Roche spent his initial engineering career in steel and water industries, working on industrial automation. Tom joined FM Global in 1993, and has worked within the loss prevention engineering team, working with local and international clients. In this role, he has helped clients to implement loss prevention programmes, successfully managed projects to install active fire protection systems, and has represented the company at numerous client seminars. Tom is currently the Engineering Manager for the UK Operations within FM Global. In this role, he is responsible for the team delivering loss prevention engineering services to plant and corporate level clients within the UK, Ireland, Scandinavia and Italy.
spacer
Tom Roche
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>

White Papers

Modular Feeding Systems for Prefilled Syringes and Injection Devices

Dividella

The pre-filled syringe and injection device is an increasingly attractive presentation for both new and established parenteral pharmaceuticals. We will explore how innovative carton packaging solutions can enhance this presentation whilst meeting the stringent requirements of product protection.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement